Hi-TIDe : Immunopeptidomics

| Research interest | Research group projects | Selected publications
 

DO_Pls-0270.jpg

Michal BASSANI-STERNBERG
Group leader
Human integrated tumor immunology discovery engine (Hi-TIDe)
Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Head of clinical Mass spectromotry unit
Center of experimental therapeutics

Phone +41 79 900 55 30
Email Michal.bassani@chuv.ch

Ludwig.jpg (Print)

 

Research interest

Our main goal is to identify clinically relevant cancer specific Human Leukocyte Antigen (HLA) ligands that will guide the development of personalized cancer immunotherapy using mass-spectrometry (MS), currently the only methodology to unbiasedly identify HLA binding peptides that are presented in vivo to cytotoxic T cells.

Research group projects

MS-based immunopeptidomics with proteomics, genomics, and transcriptomics to identify tumor-associated antigens, neoantigens and post translationally modified peptides.

We developed a high-throughput and in depth MS-based immunopeptidomics pipeline that now enables robust and reproducible sample preparation and measurement of HLA class I and HLA class II peptides. We are currently applying this methodology to identify tumor-associated HLA ligands extracted from cell lines and tumor tissues. 

Bassani1.jpg

  • We have initiated fundamental discovery work to elucidate how tumor cells present antigens and what are the bases of tumor immunogenicity.
  • We are investigating the differences between tumor types in terms of antigen presentation and how drugs modulate the immunopeptidome.
  • In collaboration with the Vital-IT group (SIB), we have established a continuous bio-informatics pipline enabling direct identification of neoantigens by combining genomic information derived from exome-seq analysis with measured immunopeptidomics data.
  • In collaboration with Prof. David Gfeller, we are improving the performance of HLA binding prediction tools by training them with our measured immunopeptidomics data.
  • This platform will be used to identify personalized neo-antigens from patients samples collected by the CTE team. These tumor-specific antigens will be further developed into personalized cancer vaccines or to enrich tumor-reactive and antigen-specific T cells for adoptive T cell-based therapies.

Selected publications

  • Müller M, Gfeller D, Coukos G and Bassani-Sternberg M* (2017) *Corresponding author. Hotspots of Antigen Presentation Revealed by HLA Ligandomics For Neoantigen PrioritizationFrontiers in Immunology, in press.

  • *Bassani-Sternberg, M., C. Chong, P. Guillaume, M. Solleder, H. Pak, P. O. Gannon, L. E. Kandalaft, G. Coukos and *D. Gfeller. Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificityPLoS Comput Biol 13(8): e1005725 (2017) *Corresponding authors
  • *Caron, E., R. Aebersold, A. Banaei-Esfahani, C. Chong and *M. Bassani-Sternberg (2017). A Case for a Human Immuno-Peptidome Project ConsortiumImmunity 47(2): 203-208 (2017). *Corresponding authors
     
  • *Bassani-Sternberg, M., *E. Braunlein, R. Klar, T. Engleitner, P. Sinitcyn, S. Audehm, M. Straub, J. Weber, J. Slotta-Huspenina, K. Specht, M. E. Martignoni, A. Werner, R. Hein, H. B. D, C. Peschel, R. Rad, J. Cox, M. Mann and A. M. Krackhardt . Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometryNat Commun 7: 13404 (2016)
     
  • Bassani-Sternberg, M. and G. Coukos. Mass spectrometry-based antigen discovery for cancer immunotherapy.Curr Opin Immunol 41: 9-17 (2016).

Group members

  • Chloe CHONG
    PhD student
  • Fabio MARINO
    Postdoctoral fellow
  • Justine MICHAUX
    Laboratory technician
  • Markus MULLER
    Senior bioinformatician
  • HuiSong PAK 
    MS operator
Ch. des Boveresses 155 - CH-1066 Epalinges
Switzerland
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
ludwig_cancer_research-logo.svg universite_de_lausanne-logo.svg chuv-logo.svg